Practical guide for identifying unmet clinical needs for biomarkers.

Current clinical pathways often lack clear guidance for evaluating new diagnostic tests. Prior research has shown that biomarker development frequently proceeds without sufficient alignment to clinical needs. While existing frameworks exist, no prior work had resolved how to systematically identify unmet needs in diagnostic testing. This gap motivated the need for a standardized approach to biomarker evaluation. Researchers have shown that misaligned testing strategies can delay clinical adoption. The field requires tools that bridge the gap between research and clinical practice. No prior work had resolved how to consistently define test purposes within clinical pathways. This uncertainty drove the development of a practical checklist to guide biomarker evaluation.

The study aimed to create a standardized framework for identifying unmet clinical needs in diagnostic testing. This paper proposes a checklist to align biomarker development with clinical pathways. The goal is to ensure that new tests meet real-world clinical requirements. The authors suggest that this approach will improve test evaluation consistency. The checklist is intended for use by multiple stakeholders in the diagnostic field. The tool supports the IOM and FDA/CE regulatory guidelines. It is designed to facilitate collaboration across disciplines. The authors propose that this framework will enhance biomarker implementation.

The EFLM TE-WG developed a conceptual framework for test evaluation. They created an interactive checklist based on clinical pathway mapping. The framework emphasizes the clinical purpose of each test. The checklist includes criteria for analytical and clinical performance. It is designed for use by laboratories, clinicians, and industry partners. The tool aligns with existing regulatory recommendations. The authors suggest that the checklist supports iterative evaluation cycles. The framework is intended to guide test development from discovery to implementation.

The framework provides a structured approach to biomarker evaluation. The checklist includes 12 key areas for identifying clinical needs. It emphasizes the importance of defining test roles within clinical pathways. The tool supports consistent terminology across stakeholders. It aligns with IOM and FDA/CE requirements. The authors suggest that the checklist improves collaboration. It is designed for use before new tests reach the market. The framework is intended to guide both research and implementation phases.

The authors propose that the framework enhances biomarker evaluation consistency. They suggest that the checklist supports stakeholder collaboration. The tool is intended to align test development with clinical needs. The framework is designed for use across disciplines. The authors propose that it improves terminology standardization. It is aligned with regulatory guidelines from IOM and FDA/CE. The tool is intended to guide test evaluation cycles. The authors suggest that it facilitates consultation and collaboration.